Want to see AU:BGT full AI Analyst Report?
BGT Stock Chart & Stats
AU$0.02
<AU$0.01(2.86%)
At close: 4:00 PM EDT
AU$0.02
<AU$0.01(2.86%)
Day’s Range― - ―
52-Week RangeAU$0.02 - AU$0.06
Previous CloseN/A
Volume129.91K
Average Volume (3M)988.87K
Market Cap
AU$8.88M
Enterprise ValueAU$4.62M
Total Cash (Recent Filing)AU$1.08M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.16
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding386,081,120
10 Day Avg. Volume246,330
30 Day Avg. Volume988,871
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)2.08
Price to Sales (P/S)0.00
P/FCF Ratio-1.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low debt provides durable financial flexibility for a loss-making company: less interest burden and lower default risk than higher-levered peers. This structural cushion makes it easier to pursue restructuring, raise incremental capital, or survive extended turnaround efforts.
Improving Free Cash Flow TrendAn improvement in free cash flow, even from negative levels, suggests initial traction on cost controls or operating efficiency. If sustained, this trend reduces required external funding and signals management's ability to stabilize operations over the medium term.
Lean Operating StructureA very small headcount implies low fixed overhead and operating leverage, which preserves runway and allows nimble pivots or partnerships. For a company burning cash, a lean cost base is a durable advantage in extending survival without immediate large capital raises.
Bears Say
Revenue CollapseZero reported revenue is a fundamental, long-lasting weakness: it indicates severe market access, demand or execution failures. Without revenue, the firm cannot self-fund operations, raising persistent funding and viability questions until revenue is demonstrably restored.
Sustained Cash BurnMulti-year negative operating and free cash flow erodes liquidity and forces reliance on external financing. Continued annual cash burn is a durable headwind that constrains investment in product, sales, or recovery efforts and increases dilution or debt risk.
Equity ErosionMaterial decline in shareholders' equity reflects accumulated losses or dilution and reduces the company's loss-absorption capacity. A weakened capital base increases insolvency risk and raises the likelihood of further dilutive financings, limiting long-term strategic options.
Bio-Gene Technology Ltd. News
BGT FAQ
What was Bio-Gene Technology Ltd.’s price range in the past 12 months?
Bio-Gene Technology Ltd. lowest share price was AU$0.02 and its highest was AU$0.06 in the past 12 months.
What is Bio-Gene Technology Ltd.’s market cap?
Bio-Gene Technology Ltd.’s market cap is AU$8.88M.
When is Bio-Gene Technology Ltd.’s upcoming earnings report date?
Bio-Gene Technology Ltd.’s upcoming earnings report date is Sep 01, 2026 which is in 27 days.
How were Bio-Gene Technology Ltd.’s earnings last quarter?
Bio-Gene Technology Ltd. released its earnings results on Feb 23, 2026. The company reported -AU$0.005 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.005.
Is Bio-Gene Technology Ltd. overvalued?
According to Wall Street analysts Bio-Gene Technology Ltd.’s price is currently Overvalued.
Does Bio-Gene Technology Ltd. pay dividends?
Bio-Gene Technology Ltd. does not currently pay dividends.
What is Bio-Gene Technology Ltd.’s EPS estimate?
Bio-Gene Technology Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bio-Gene Technology Ltd. have?
Bio-Gene Technology Ltd. has 386,081,120 shares outstanding.
What happened to Bio-Gene Technology Ltd.’s price movement after its last earnings report?
Bio-Gene Technology Ltd. reported an EPS of -AU$0.005 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 6.452%.
Which hedge fund is a major shareholder of Bio-Gene Technology Ltd.?
Currently, no hedge funds are holding shares in AU:BGT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bio-Gene Technology Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:BGT Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-52.63%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-21.07%
Trailing 12-Months
Technical Analysis
Biotron
―
Vectus Biosystems Limited
―
Tissue Repair Ltd
―
Regeneus Ltd.
―
Botanix Pharmaceuticals Limited
―